{"organizations": [], "uuid": "cd179c8a09f6b3cb55c792a0b998e03c8d2c3063", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-exelixis-announces-amendment-to-pr/brief-exelixis-announces-amendment-to-protocol-for-phase-1b-trial-of-cabozantinib-in-combination-with-atezolizumab-idUSFWN1OZ0PV", "country": "US", "domain_rank": 408, "title": "BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T15:08:00.000+02:00", "replies_count": 0, "uuid": "cd179c8a09f6b3cb55c792a0b998e03c8d2c3063"}, "author": "", "url": "https://www.reuters.com/article/brief-exelixis-announces-amendment-to-pr/brief-exelixis-announces-amendment-to-protocol-for-phase-1b-trial-of-cabozantinib-in-combination-with-atezolizumab-idUSFWN1OZ0PV", "ord_in_thread": 0, "title": "BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "atezolizumab reuters", "sentiment": "none"}, {"name": "exelixis inc", "sentiment": "none"}, {"name": "exelixis inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 1:09 PM / Updated 7 minutes ago BRIEF-Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab Reuters Staff \nJan 4 (Reuters) - Exelixis Inc: \n* EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB \n* EXELIXIS INC - AMENDMENT ADDS FOUR NEW EXPANSION COHORTS TO PHASE 1B TRIAL, WHICH WILL NOW INCLUDE PATIENTS WITH NSCLC AND CRPC Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T15:08:00.000+02:00", "crawled": "2018-01-04T15:28:09.005+02:00", "highlightTitle": ""}